文献速递基础与转化研究新药、器械与细胞基因治疗研发

靶向癌症中的KRAS

Targeting KRAS in cancer.
PubMed 文献 · Nat Med · 2024-04-18

RAS家族变异(多数为KRAS)是人类癌症中最常见的热点突变,与不良预后相关。近四十年来KRAS曾被认为不可成药,但生物工程与有机化学等领域进展使直接靶向KRAS成为可能。首个成功是非小细胞肺癌中KRAS p.Gly12Cys(G12C)的等位基因特异性靶向,导致索托拉西布和阿达格拉西布两种药物获批。本文概述RAS病理生物学、多种恶性肿瘤的治疗策略(包括on/off开关等位基因特异性及pan-RAS抑制剂)、免疫治疗及联合靶向策略,总结原发与获得性耐药机制,并展望KRAS治疗前景。

要点

  • KRAS p.Gly12Cys(G12C)等位基因特异性抑制剂索托拉西布和阿达格拉西布已获监管批准用于非小细胞肺癌。
  • 靶向G12C以外其他变异体的抑制剂在胰腺癌等高难治性恶性肿瘤中显示初步抗肿瘤活性。
  • 本文综述RAS靶向的等位基因特异性(on/off开关)与pan-RAS抑制剂、免疫治疗及联合策略,并总结原发与获得性耐药机制。

核心结论

  • 直接靶向KRAS已成为可能,首个成功为KRAS G12C等位基因特异性抑制剂在非小细胞肺癌中的监管批准,其他变异体抑制剂显示初步抗肿瘤活性。
  • 本文总结KRAS病理生物学、治疗策略、耐药机制与联合方案,并勾勒KRAS治疗的未来蓝图,预期产生深远临床影响。

研究设计与样本

  • 本文为综述,检索范围未在摘要中报告。

主要发现

  • RAS家族变异(多数涉及KRAS)是人类癌症中最常见的 hotspot 突变,与不良预后相关。
  • KRAS曾被认为不可成药近四十年,部分因其结构缺乏小分子结合位点。
  • 非小细胞肺癌中KRAS p.Gly12Cys(G12C)的等位基因特异性靶向取得首批成功,索托拉西布和阿达格拉西布两种药物获监管批准。
  • 靶向G12C以外其他变异体的抑制剂在胰腺癌等高难治性恶性肿瘤中显示初步抗肿瘤活性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RAS family variants-most of which involve KRAS-are the most commonly occurring hotspot mutations in human cancers and are associated with a poor prognosis. For almost four decades, KRAS has been considered undruggable, in part due to its structure, which lacks small-molecule binding sites. But recent developments in bioengineering, organic chemistry and related fields have provided the infrastructure to make direct KRAS targeting possible. The first successes occurred with allele-specific targeting of KRAS p.Gly12Cys (G12C) in non-small cell lung cancer, resulting in regulatory approval of two agents-sotorasib and adagrasib. Inhibitors targeting other variants beyond G12C have shown preliminary antitumor activity in highly refractory malignancies such as pancreatic cancer. Herein, we outline RAS pathobiology with a focus on KRAS, illustrate therapeutic approaches across a variety of malignancies, including emphasis on the 'on' and 'off' switch allele-specific and 'pan' RAS inhibitors, and review immunotherapeutic and other key combination RAS targeting strategies. We summarize mechanistic understanding of de novo and acquired resistance, review combination approaches, emerging technologies and drug development paradigms and outline a blueprint for the future of KRAS therapeutics with anticipated profound clinical impact.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Singhal A, Li BT, O'Reilly EM, et al. Targeting KRAS in cancer. Nat Med. 2024. PMID: 38637634. doi:10.1038/s41591-024-02903-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。